Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

British Journal of Cancer

Volumn 96, Issue 3, 2007, Pages 457-463

  Nakano, Y ^a   Tanno, S ^a   Koizumi, K ^a   Nishikawa, T ^a   Nakamura, K ^a   Minoguchi, M ^a   Izawa, T ^a   Mizukami, Y ^a   Okumura, T ^a   Kohgo, Y ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Deoxycytidine kinase; Gemcitabine resistance; Nucleoside transporter; Pancreatic cancer; Predictive marker; Ribonucleotide reductase

Indexed keywords

DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; MESSENGER RNA; MOLECULAR MARKER; PROTEIN; PROTEIN RRM1; PROTEIN RRM2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER PATIENT; CANCER RESISTANCE; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TRANSPORT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOLECULAR CLONING; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS; STATISTICAL SIGNIFICANCE; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; HUMANS; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 33846816556     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603559     Document Type: Article

References (29)

1. Agarwal B, Abu-Hamda E, Molke KL, Correa AM, Ho L (2004) Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am J Gastroenterol 99: 844-850
2. Arnold NB, Ketterer K, Kleeff J, Friess H, Buchler MW, Korc M (2004) Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer. Cancer Res 64: 3599-3606
3. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413
4. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J (1996) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101-105
5. Cory JG, Sato A (1983) Regulation of ribonucleotide reductase activity in mammalian cells. Mol Cell Biochem 53-54: 257-266
6. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA (2004) An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64: 3761-3766
7. Fan H, Villegas C, Wright JA (1996) Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci USA 93: 14036-14040
8. Galmarini CM, Clarke ML, Jordheim L, Santos CL, Cros E, Mackey JR, Dumontet C (2004) Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol 24: 8
9. Galmarini CM, Mackey JR, Dumontet C (2001) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15: 875-890
10. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M (2003) Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 9: 5000-5008
11. Goan YG, Zhou B, Hu E, Mi S, Yen Y (1999) Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2- difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59: 4204-4207
12. Habiro A, Tanno S, Koizumi K, Izawa T, Nakano Y, Osanai M, Mizukami Y, Okumura T, Kohgo Y (2004) Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells. Biochem Biophys Res Commun 316: 71-77
13. Jordheim L, Galmarini CM, Dumontet C (2003) Drug resistance to cytotoxic nucleoside analogues. Curr Drug Targets 4: 443-460
14. Jung CP, Motwani MV, Schwartz GK (2001) Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 7: 2527-2536
15. Koc A, Mathews CK, Wheeler LJ, Gross MK, Merrill GF (2006) Thioredoxin is required for deoxyribonucleotide pool maintenance during S phase. J Biol Chem 281: 15058-15063
16. Koizumi K, Tanno S, Nakano Y, Habiro A, Izawa T, Mizukami Y, Okumura T, Kohgo Y (2005) Activation of p38 mitogen-activated protein kinase is necessary for gemcitabine-induced cytotoxicity in human pancreatic cancer cells. Anticancer Res 25: 3347-3353
17. Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363: 1049-1057
18. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass CE (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58: 4349-4357
19. Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE, Young JD (1999) Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 91: 1876-1881
20. Pellise M, Castells A, Gines A, Agrelo R, Sole M, Castellvi-Bel S, Fernandez-Esparrach G, Llach J, Esteller M, Bordas JM, Pique JM (2004) Detection of lymph node micrometastases by gene promoter hypermethylation in samples obtained by endosonography-guided fine-needle aspiration biopsy. Clin Cancer Res 10: 4444-4449
21. Plunkett W, Huang P, Searcy CE, Gandhi V (1996) Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23: 3-15
22. Rauchwerger DR, Firby PS, Hedley DW, Moore MJ (2000) Equilibrative- sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 60: 6075-6079
23. Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM, Hyde RJ, Karpinski E, Cass CE, Baldwin SA, Young JD (2001) Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Mol Membr Biol 18: 65-72
24. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris III HA, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD (1996) A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7: 347-353
25. Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM, Peters GJ (1994) Development and molecular characterization of a 2′, 2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 54: 4138-4143
26. Tada M, Komatsu Y, Kawabe T, Sasahira N, Isayama H, Toda N, Shiratori Y, Omata M (2002) Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. Am J Gastroenterol 97: 2263-2270
27. Thelander L, Berg P (1986) Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase. Mol Cell Biol 6: 3433-3442
28. Van der Wilt CL, Kroep JR, Bergman AM, Loves WJ, Alvarez E, Talianidis I, Eriksson S, Van Groeningen CJ, Pinedo HM, Peters GJ (2000) The role of deoxycytidine kinase in gemcitabine cytotoxicity. Adv Exp Med Biol 486: 287-290
29. Zhou BS, Tsai P, Ker R, Tsai J, Ho R, Yu J, Shih J, Yen Y (1998) Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 16: 43-49